Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss

Core Viewpoint - Cyclacel Pharmaceuticals reported a quarterly loss of $0.18 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.54, marking an earnings surprise of 66.67% [1] Financial Performance - The company posted revenues of $0.01 million for the quarter ended September 2024, consistent with the Zacks Consensus Estimate, but down from $0.02 million a year ago [2] - Over the last four quarters, Cyclacel has surpassed consensus EPS estimates four times, but has not beaten consensus revenue estimates during the same period [2] Stock Performance - Cyclacel shares have declined approximately 83.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] - The current Zacks Rank for Cyclacel is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $0.01 million, and for the current fiscal year, it is -$2.29 on revenues of $0.05 million [7] - The estimate revisions trend for Cyclacel is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - The Medical - Biomedical and Genetics industry, to which Cyclacel belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]